Choosing drugs on price alone will stifle innovation, says reportBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6065 (Published 10 November 2016) Cite this as: BMJ 2016;355:i6065
- Nigel Hawkes
The NHS in England should not focus exclusively on price when buying medicines, says a new report published by the London School of Economics (LSE).1
Doing so risks endangering constructive partnerships between clinicians, NHS managers, and drug companies and conflicts with the government’s aim of balancing affordability with encouraging innovation, the report warned.
While the Pharmaceutical Price Regulation Scheme and HM Treasury both seek to strike this balance, the report warned that growing pressure on NHS budgets will encourage cost saving to the detriment of cooperation and innovation.
Tender Loving Care? was written by Andrew Bonser, a consultant who has worked for Pfizer and Boots; Panos Kanavos, deputy director of LSE Health; and David Taylor, emeritus professor of pharmaceutical and public health policy at University College London. It was commissioned and funded …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial